EGFR Exon 19 Deletion | Cancer Search

mutation class

Small Mutation

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

227 sites for NCT04988295

EGFR Exon 19 Deletion, +1 more biomarker

Non-Squamous Non-Small Cell Lung Carcinoma

amivantamab, +3 more drugs

chemotherapy, +1 more type

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

259 sites for NCT04487080

EGFR Exon 19 Deletion, +1 more biomarker

Non-Small Cell Lung Carcinoma

amivantamab, +1 more drug

targeted therapy

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

104 sites for NCT04619004

EGFR Exon 19 Deletion, +1 more biomarker

Non-Small Cell Lung Carcinoma

patritumab deruxtecan

chemotherapy, +1 more type

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

170 sites for NCT04351555

EGFR Exon 19 Deletion, +1 more biomarker

Non-Squamous Non-Small Cell Lung Carcinoma

carboplatin, +3 more drugs

chemotherapy, +1 more type

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

343 sites for NCT04181060

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

bevacizumab, +1 more drug

targeted therapy

Show 67 Trials for EGFR Exon 19 Deletion